Introduction
Strattera is the product name for atomoxetine. Physicians prescribe it to both children and adults diagnosed with attention deficit hyperactivity disorder, one of the most common childhood disorders that can continue into adulthood. Those with attention deficit hyperactivity disorder (ADHD) have trouble paying attention and controlling their behavior.
Strattera is in a class of medications known as selective norepinephrine reuptake inhibitors (SNRIs). It works by increasing the levels of norepinephrine, a substance in the brain that helps control behavior. (1)
Use of strattera: attention deficit hyperactivity disorder. (2) possible Said effects: (2)
Xerostomia Headache
Abdominal pain Decreased appetite …show more content…
Sudden death has been reported in adults and children taking CNS stimulant treatment. Additionally, stroke, myocardial infarction, chest pain, syncope, arrhythmias and other symptoms have been reported in adults under treatment. A careful assessment of the cardiovascular status should be done in patients being considered for treatment. This includes family history, physical exam and further cardiac evaluation (EKG and echocardiogram). Patients who develop symptoms should have a detailed cardiac evaluation and if needed, treatment should be suspended.
CNS stimulants - hypertension
CNS stimulant medications have shown to increase blood pressure and their use is contraindicated in patients with severe hypertension. Caution should be used when administering to patients with preexisting high blood pressure and other cardiovascular conditions. All patients under treatment should be regularly monitored for changes in blood pressure and heart rate
Strattera (atomoxetine) disease …show more content…
Poor metabolizer Two inactive alleles Standard dose. Dose increase probably not necessary; be alert to adverse drug events.
Atomoxetine is primarily metabolized through the CYP2D6 enzymatic pathway. The main metabolite, 4-hydroxyatomoxetine, is equipotent to atomoxetine as an inhibitor of the norepinephrine transport, but is found at much lower levels in the plasma. In individuals who lack CYP2D6 activity (poor metabolizers), 4-hydroxyatomoxetine is formed by other CYP enzymes, but at a much slower rate. CYP2C19, along with other CYP enzymes, forms the metabolite N-Desmethylatomoxetine. Although this metabolite has substantially less pharmacological activity compared to atomoxetine, and is present at much lower plasma concentrations, one study found that genetic polymorphisms of the CYP2C19 gene also influenced the pharmacokinetics of atomoxetine.
Atomoxetine has a wide therapeutic window, but the risk of adverse effects may be increased by the presence of CYP2D6 genetic variants. Common adverse effects of atomoxetine therapy include weight loss, headache, and irritability. Psychiatric side effects may also occur; these include anxiety, depression, and the development of suicidal
Strattera is the product name for atomoxetine. Physicians prescribe it to both children and adults diagnosed with attention deficit hyperactivity disorder, one of the most common childhood disorders that can continue into adulthood. Those with attention deficit hyperactivity disorder (ADHD) have trouble paying attention and controlling their behavior.
Strattera is in a class of medications known as selective norepinephrine reuptake inhibitors (SNRIs). It works by increasing the levels of norepinephrine, a substance in the brain that helps control behavior. (1)
Use of strattera: attention deficit hyperactivity disorder. (2) possible Said effects: (2)
Xerostomia Headache
Abdominal pain Decreased appetite …show more content…
Sudden death has been reported in adults and children taking CNS stimulant treatment. Additionally, stroke, myocardial infarction, chest pain, syncope, arrhythmias and other symptoms have been reported in adults under treatment. A careful assessment of the cardiovascular status should be done in patients being considered for treatment. This includes family history, physical exam and further cardiac evaluation (EKG and echocardiogram). Patients who develop symptoms should have a detailed cardiac evaluation and if needed, treatment should be suspended.
CNS stimulants - hypertension
CNS stimulant medications have shown to increase blood pressure and their use is contraindicated in patients with severe hypertension. Caution should be used when administering to patients with preexisting high blood pressure and other cardiovascular conditions. All patients under treatment should be regularly monitored for changes in blood pressure and heart rate
Strattera (atomoxetine) disease …show more content…
Poor metabolizer Two inactive alleles Standard dose. Dose increase probably not necessary; be alert to adverse drug events.
Atomoxetine is primarily metabolized through the CYP2D6 enzymatic pathway. The main metabolite, 4-hydroxyatomoxetine, is equipotent to atomoxetine as an inhibitor of the norepinephrine transport, but is found at much lower levels in the plasma. In individuals who lack CYP2D6 activity (poor metabolizers), 4-hydroxyatomoxetine is formed by other CYP enzymes, but at a much slower rate. CYP2C19, along with other CYP enzymes, forms the metabolite N-Desmethylatomoxetine. Although this metabolite has substantially less pharmacological activity compared to atomoxetine, and is present at much lower plasma concentrations, one study found that genetic polymorphisms of the CYP2C19 gene also influenced the pharmacokinetics of atomoxetine.
Atomoxetine has a wide therapeutic window, but the risk of adverse effects may be increased by the presence of CYP2D6 genetic variants. Common adverse effects of atomoxetine therapy include weight loss, headache, and irritability. Psychiatric side effects may also occur; these include anxiety, depression, and the development of suicidal